GLIOBLASTOMA FOUNDATION INC logo

Thomas F. Kirby Glioblastoma Foundation Award for Drug Development

GLIOBLASTOMA FOUNDATION INC

Funding Amount

Varies

Deadline

Rolling / Open

Grant Type

foundation

Overview

Thomas F. Kirby Glioblastoma Foundation Award for Drug Development

Funder: Glioblastoma Foundation Inc (NC, US)

Focus Area: Glioblastoma drug development and therapeutic research

Geographic Scope: United States

Award Purpose: Supports research projects focused on developing new drugs and therapies to treat glioblastoma, particularly targeted therapeutic approaches.

Background

The inaugural 2018 award was presented to Dr. Gregory Riggins, M.D., Ph.D., Professor of Neurosurgery and Oncology at Johns Hopkins University School of Medicine, for his research project "Development of an improved version of the anti-parasitic agent Mebendazole to treat glioblastoma."

Glioblastoma Foundation Mission

Mission: To transform the standard of care for glioblastoma by supporting the development of new drugs and other effective therapies. The foundation recognizes that each glioblastoma is different and no single drug will work for everyone, thus supporting development of targeted therapies for glioblastoma.

Current Standard of Care

The current standard of care for glioblastoma consisting of radiation and chemotherapy is ineffective.

    Contact & More Information

  • Website: glioblastomafoundation.org
  • Organization: Glioblastoma Foundation (501(c)(3) non-profit charitable organization)

Focus Areas & Funding Uses

Fields of Work

science-researchcancer

Categories

Browse similar grants by category

Related Grants

Similar grants from this funder and related organizations

Ready to apply for Thomas F. Kirby Glioblastoma Foundation Award for Drug Development?

Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.